Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Genoa – page 31

707 clinical trials in Genoa, Italy across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Genoa at a glance
707
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

707 trials in Genoa

Open in trial search

Sickle cell disease

Not yet recruiting

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-2-Hydroxy-6-((4-(2-(2-Hydroxyethyl)Nicotinoyl)Morpholin-3-Yl)Methoxy)Benzaldehyde
  • Sponsor:Global Blood Therapeutics Inc.

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:Sarepta Therapeutics Inc.

Prostate cancer

Not yet recruiting

Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:64CU-PSMA I&T
  • Sponsor:Curium US LLC

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Cardiac arrest

Not yet recruiting

Study on the Safety of Argon and Oxygen Ventilation for Patients Resuscitated from Cardiac Arrest

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Argon
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Lung carcinoma cell type unspecified recurrent

Not yet recruiting

Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Pulmonary embolism+1

Not yet recruiting

Study on Sulodexide for Preventing Recurrence of Blood Clots in Elderly Patients After First Episode of Deep Vein Thrombosis or Pulmonary Embolism

Registered drug
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Sulodexide
  • Sponsor:Fondazione Arianna Anticoagulazione

Chronic kidney disease

Not yet recruiting

Study on Finerenone for Slowing Chronic Kidney Disease Progression in Patients Receiving Standard Care

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:The George Institute For Global Health

Breast cancer female

Not yet recruiting

Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Michelangelo

Anaemia of chronic disease

Not yet recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa
  • Sponsor:Genexine Inc.

Hypophosphatasia

Not yet recruiting

Study of ALXN1850 for Children Aged 2 to 12 with Hypophosphatasia Who Have Not Previously Received Asfotase Alfa Treatment

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Alxn1850
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Genoa

What the registry says about research in the country

01 Infectious Disease Research

Clinical studies focusing on viral infections and prevention strategies, including trials evaluating vaccines against Herpes Zoster and Cytomegalovirus in healthy adults.

  • Vaccine effectiveness studies
  • Immune response monitoring
  • Prevention protocols

Research includes evaluation of antibiotic protocols in dental procedures and viral-specific treatments for immunocompromised patients.

02 Oncology Studies

Innovative research in cancer treatment, including trials for breast cancer prevention, advanced solid tumors, and targeted therapies for colorectal cancer.

  • Preventive interventions
  • Novel combination therapies
  • Diagnostic imaging

Studies encompass both early intervention strategies and treatments for advanced stages of various cancers.

03 Neurological Disorders

Investigations into treatments for Multiple Sclerosis and other neurological conditions, with focus on disease progression and innovative therapies.

  • Progressive MS treatments
  • Neuromuscular monitoring
  • Safety assessments

Clinical trials evaluating new therapeutic approaches for various neurological conditions including Dravet Syndrome.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.